1 year ago
India Investigates Ranitidine Due To Carcinogen Concerns
Imagine a medicine called Ranitidine that helps with tummy troubles.
Scientists are worried because it might have a substance called NDMA, which could cause cancer.
Because of this, the government is making sure the medicine is checked very carefully.
They're telling the companies that make it to test it and maybe change how long it lasts on the shelf.
Doctors also say there are other, safer medicines that can do the same job.
NDMA has caused problems in other countries too, so everyone is being extra cautious to make sure the medicine is safe to use.
CDSCO directs Ranitidine manufacturers to monitor NDMA levels due to carcinogen concerns.
The move follows a recommendation from the Drugs Technical Advisory Board and expert committee findings.
Manufacturers must adopt risk-based measures, including shelf-life limits and enhanced testing.
NDMA, a probable human carcinogen, triggered global regulatory scrutiny of Ranitidine.
Experts suggest safer alternatives like Famotidine and Pantoprazole exist.
- Who
- The CDSCO, DTAB, and manufacturers of Ranitidine are involved.
- What
- CDSCO is investigating Ranitidine for potential carcinogen contamination.
- Where
- India
- When
- The decision followed a DTAB meeting on April 28, 2025 and expert committee reports.
- Why
- Concerns about NDMA, a probable carcinogen, found in Ranitidine.
Doctors Express Caution
Varying Opinions
Treatment Choice
Doctors Express Caution
Dr. Shankar suggests avoiding Ranitidine for safer alternatives.
Varying Opinions
N/A
Drug Usage
Doctors Express Caution
Doctors suggest Ranitidine usage has reduced in metro cities.
Varying Opinions
Dr. Chauhan notes it's still prescribed in Tier 1/2 cities.
Key facts
- Drug Name
- Ranitidine
- Issue
- NDMA impurity (potential carcinogen)
- Regulatory Body
- CDSCO
- Action
- Monitoring NDMA levels, shelf-life reduction, enhanced testing
- Alternative Medicines
- Famotidine and Pantoprazole
- Classification
- Probable human carcinogen (Group 2A)
